CANTOS: A Gigantic Proof-of-Concept Trial

Circulation Research

Volumn 121, Issue 12, 2017, Pages 1320-1322

  Ibañez, Borja ^a,b   Fuster, Valentin ^c,d  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b 28400 Madrid   (Spain)

^c CIBER de Enfermedades CardioVasculares ^*  (Spain)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; biomarkers; C reactive protein; cholesterol, LDL; inflammation

Indexed keywords

CANAKINUMAB; INTERLEUKIN 1BETA; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG FATALITY; DRUG TARGETING; HEART INFARCTION; HUMAN; INFECTION; INFLAMMATION; PRIORITY JOURNAL; PROOF-OF-CONCEPT TRIAL; REVIEW; RISK; SEPSIS; SIDE EFFECT; THROMBOSIS; ECONOMICS; PROOF OF CONCEPT; SPAIN;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; PROOF OF CONCEPT STUDY; SPAIN; THROMBOSIS;

EID: 85037118294     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.312200     Document Type: Review

References (15)

1. Ridker PM. C-reactive protein, the prediction of cardiovascular events among those at intermediate risk: Moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129-2138. doi: 10.1016/j.jacc.2007.02.052.
2. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men, women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207. doi: 10.1056/NEJMoa0807646.
3. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate, mortality in patients with rheumatoid arthritis: A prospective study. Lancet. 2002;359:1173-1177. doi: 10.1016/S0140-6736(02)08213-2.
4. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use, the risk of acute myocardial infarction. Arthritis Rheum. 2006;55:531-536. doi: 10.1002/art.22094.
5. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118:145-156. doi: 10.1161/CIRCRESAHA.115.306656.
6. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 1996;16:1000-1006.
7. Choudhury RP, Birks JS, Mani V, et al. Arterial effects of canakinumab in patients with atherosclerosis, type 2 diabetes or glucose intolerance. J Am Coll Cardiol. 2016;68:1769-1780. doi: 10.1016/j.jacc.2016.07.768.
8. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-1131. doi: 10.1056/NEJMoa1707914.
9. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ; CANTOS Trial Group. Effect of interleukin-1 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1833-1842. doi: 10.1016/S0140-6736(17)32247-X.
10. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) [published online ahead of print August 26, 2017]. Eur Heart J. doi: 10.1093/eurheartj/ehx393. https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehx393.
11. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee, Investigators. Evolocumab, clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-1722. doi: 10.1056/NEJMoa1615664.
12. Cannon CP, Blazing MA, Giugliano RP, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397. doi: 10.1056/NEJMoa1410489.
13. Ridker PM. How common is residual inflammatory risk Circ Res. 2017;120:617-619. doi: 10.1161/CIRCRESAHA.116.310527.
14. Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2:1069-1078. doi: 10.1001/jamacardio.2017.2762.
15. López-Melgar B, Fernández-Friera L, Oliva B, Garciá-Ruiz JM, Penãlvo JL, Gómez-Talavera S, Sánchez-González J, Mendiguren JM, Ibáñez B, Fernández-Ortiz A, Sanz J, Fuster V. Subclinical atherosclerosis burden by 3D ultrasound in mid-life: The PESA study. J Am Coll Cardiol. 2017;70:301-313. doi: 10.1016/j.jacc.2017.05.033.